30 Dec 2011 07:00
FOR IMMEDIATE RELEASE
Total Voting Rights
London, December 30, 2011 - In accordance with the FSA's Disclosure and Transparency Rule 5.6.1, Silence Therapeutics plc (the "Company") announces that the Company's issued share capital consists of 577,114,517 ordinary shares of 1 pence each ("Ordinary Shares") with voting rights. There are no Ordinary Shares held in treasury.
Therefore the total number of voting rights in Silence Therapeutics plc at the date of this notice is 577,114,517.
The above figure (577,114,517) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Silence Therapeutics plc under the FSA's Disclosure and Transparency Rules.
--Ends--
For further information, please contact:
Silence Therapeutics Singer Capital Markets Thomas Christ©ly/Max Herrmann Shaun Dobson/Claes Sp¥ng +49 30 9489 2800/+44 20 7491 6520 +44 20 3205 7500 t.christely@silence-therapeutics.com shaun.dobson@singercm.com m.herrmann@silence-therapeutics.com claes.spang@singercm.com M:Communications Peter Laing / Emma Thompson / Claire Dickinson +44 20 7920 2345 / +44 20 7920 2342 healthcare@mcomgroup.com Notes for editors
About Silence Therapeutics plc (www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.
The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEXâ„¢, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes.
Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.
The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEXâ„¢. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the first half of 2012.
The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.
Forward-Looking Statements
This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.
# # #
XLON